The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial

Qiao Li,Jiaxuan Liu,Qingyuan Zhang,Quchang Ouyang,Yang Zhang,Qiang Liu,Tao Sun,Feng Ye,Baochun Zhang,Summer Xia,Bangyong Zhang,Binghe Xu
DOI: https://doi.org/10.1038/s41467-024-45160-y
IF: 16.6
2024-02-03
Nature Communications
Abstract:Abstract This multicenter, phase II study (NCT03872791) aims to evaluate the efficacy and safety of the anti-PD-L1/CTLA-4 bispecific antibody KN046 combined with nab-paclitaxel in the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC). The primary endpoints included objective response rate (ORR) and duration of response (DoR), and secondary endpoints included progression-free survival (PFS), overall survival (OS) rate, safety, and the correlation of PD-L1 status with clinical efficacy. This trial met pre-specified endpoints. 27 female patients were enrolled sequentially to receive KN046 in two dose levels (3 mg/kg or 5 mg/kg). Among the 25 evaluable patients, the ORR achieved 44.0% (95% CI, 24.4% − 65.1%), and the median DoR was not mature. The median PFS reached 7.33 months (95%CI, 3.68 − 11.07 months), and the median OS was 30.92 months (95%CI, 14.75 - NE months). In PD-L1 positive patients, PFS was 8.61 months (versus 4.73 months) and the 2-year OS rate was 62.5% (versus 57.1%) compared to PD-L1 negative patients. Patients tolerated well the combination therapy. In general, KN046 combined with nab-paclitaxel showed favorable efficacy and survival benefits with tolerable toxicity in the first-line treatment of metastatic TNBC, especially PD-L1 positive, which is worth further investigation.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to evaluate the efficacy and safety of KN046 (an anti - PD - L1/CTLA - 4 bispecific antibody) combined with albumin - bound paclitaxel (nab - paclitaxel) in the first - line treatment of metastatic triple - negative breast cancer (TNBC). Specifically, the main endpoints of the study include objective response rate (ORR) and duration of response (DoR), while the secondary endpoints include progression - free survival (PFS), overall survival (OS) rate, safety, and the correlation between PD - L1 status and clinical efficacy. ### Research Background - **Triple - negative breast cancer (TNBC)**: This is a subtype of breast cancer, with estrogen receptor (ER) and progesterone receptor (PR) expressions both less than 1%, and human epidermal growth factor receptor 2 (HER2) negative, accounting for 15% - 20% of all breast cancers. TNBC is characterized by a high risk of early recurrence, a high frequency of metastasis, and a poor prognosis. - **Immune checkpoint inhibitors (ICIs)**: In recent years, due to the high heterogeneity and immunogenicity of TNBC, ICIs have become one of the most promising treatment strategies to improve long - term survival rates. Especially for TNBC patients with high PD - L1 expression, high tumor mutation burden (TMB), and a large number of tumor - infiltrating lymphocytes (TILs), ICIs show better efficacy. - **KN046**: This is a recombinant humanized anti - PD - L1/CTLA - 4 bispecific single - domain antibody - Fc fusion protein, which can simultaneously block the binding of CTLA - 4 to CD80/85 and the binding of PD - L1 to programmed cell death - 1 (PD - 1), thereby inhibiting the immunosuppressive effect, restoring the effector immune response of T cells to tumors, and deleting regulatory T cells (Treg cells) in the tumor microenvironment. ### Research Design - **Study type**: This is a multicenter, open - label phase II trial. - **Study subjects**: 27 female patients with untreated locally advanced inoperable or metastatic TNBC. - **Treatment plan**: Patients were assigned to two dose groups and received KN046 3 mg/kg Q2W (once every two weeks) or 5 mg/kg Q2W, combined with nab - paclitaxel treatment. - **Evaluation indicators**: - **Main endpoints**: Objective response rate (ORR) and duration of response (DoR). - **Secondary endpoints**: Progression - free survival (PFS), overall survival (OS) rate, safety, and the correlation between PD - L1 status and clinical efficacy. ### Main Findings - **Overall efficacy**: Among 25 evaluable patients, the ORR reached 44.0% (95% CI: 24.4% - 65.1%), and the median DoR has not been reached yet. The median PFS was 7.33 months (95% CI: 3.68 - 11.07 months), and the median OS was 30.92 months (95% CI: 14.75 - NE months). - **Efficacy in PD - L1 - positive patients**: The median PFS in PD - L1 - positive patients was 8.61 months, and the 2 - year OS rate was 62.5%, while the median PFS in PD - L1 - negative patients was 4.73 months, and the 2 - year OS rate was 57.1%. - **Safety**: All patients reported treatment - related adverse events (TRAEs), and the incidence of ≥3 - level TRAEs was 66.7%. The most common TRAEs included neutropenia, leukopenia, alopecia, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST). Most ≥3 - level TRAEs were hepatotoxicity and hematotoxicity, which were reversible after symptomatic and supportive treatment. ### Conclusions - **Main conclusions**: KN046 combined with nab - paclitaxel shows good clinical efficacy and encouraging survival results in the first - line treatment of locally advanced inoperable or metastatic TNBC, especially in PD - L1 - positive patients. The safety of this combination therapy is manageable and is worthy of further verification in subsequent studies with a larger sample size. - **Future directions**: Larger - scale phase III trials are needed to determine the optimal dose level and to compare with other standard treatment strategies or immunotherapy combined with chemotherapy. In addition, other predictive biomarkers need to be explored to optimize efficacy and reduce toxicity.